Marion Wealth Management Invests $241,000 in Axon Enterprise, Inc. (NASDAQ:AXON)

Marion Wealth Management acquired a new stake in Axon Enterprise, Inc. (NASDAQ:AXON) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 406 shares of the biotechnology company’s stock, valued at approximately $241,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Insigneo Advisory Services LLC lifted its holdings in Axon Enterprise by 1.4% during the 3rd quarter. Insigneo Advisory Services LLC now owns 1,568 shares of the biotechnology company’s stock valued at $627,000 after purchasing an additional 22 shares during the last quarter. Menard Financial Group LLC raised its position in shares of Axon Enterprise by 0.8% in the third quarter. Menard Financial Group LLC now owns 3,014 shares of the biotechnology company’s stock valued at $1,204,000 after purchasing an additional 24 shares during the period. PFG Investments LLC lifted its stake in shares of Axon Enterprise by 0.6% during the 3rd quarter. PFG Investments LLC now owns 3,872 shares of the biotechnology company’s stock worth $1,547,000 after buying an additional 25 shares during the last quarter. Gladstone Institutional Advisory LLC boosted its holdings in shares of Axon Enterprise by 1.6% during the 3rd quarter. Gladstone Institutional Advisory LLC now owns 1,641 shares of the biotechnology company’s stock worth $656,000 after buying an additional 26 shares during the period. Finally, Mather Group LLC. grew its stake in Axon Enterprise by 3.7% in the 3rd quarter. Mather Group LLC. now owns 759 shares of the biotechnology company’s stock valued at $303,000 after buying an additional 27 shares during the last quarter. 79.08% of the stock is owned by institutional investors.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, Director Michael Garnreiter sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $437.98, for a total transaction of $437,980.00. Following the sale, the director now directly owns 26,259 shares of the company’s stock, valued at $11,500,916.82. The trade was a 3.67 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Jeffrey C. Kunins sold 21,834 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $593.88, for a total transaction of $12,966,775.92. Following the completion of the transaction, the insider now owns 154,394 shares of the company’s stock, valued at approximately $91,691,508.72. This trade represents a 12.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 51,545 shares of company stock valued at $31,159,317 in the last quarter. Insiders own 6.10% of the company’s stock.

Axon Enterprise Price Performance

NASDAQ:AXON traded down $1.32 during trading hours on Monday, hitting $568.68. The company’s stock had a trading volume of 422,321 shares, compared to its average volume of 713,845. Axon Enterprise, Inc. has a twelve month low of $246.99 and a twelve month high of $698.67. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. The stock has a fifty day simple moving average of $607.29 and a 200-day simple moving average of $451.03. The company has a market capitalization of $43.36 billion, a P/E ratio of 146.95, a PEG ratio of 14.19 and a beta of 1.04.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. The Goldman Sachs Group boosted their price objective on Axon Enterprise from $385.00 to $441.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. TD Cowen started coverage on Axon Enterprise in a research report on Wednesday, January 8th. They set a “buy” rating and a $700.00 price objective on the stock. Morgan Stanley raised shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $500.00 to $700.00 in a research report on Tuesday, December 3rd. Northland Securities lifted their price objective on shares of Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a research note on Monday, November 11th. Finally, Needham & Company LLC increased their target price on shares of Axon Enterprise from $525.00 to $600.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. One analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $504.92.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.